Evidence map›Paper›PMID 20043032›Full record

ArticlePLoS currents2009

Is a Mass Immunization Program for Pandemic (H1N1) 2009 Good Value for Money? Early Evidence from the Canadian Experience.

Beate Sander, Chris Bauch, David N Fisman, R Fowler, Jeffrey C Kwong, Allison McGeer, Marija Zivkovic Gojovic, Murray Krahn

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS currents, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Beate SanderDepartment of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada; University of Guelph; Dalla Lana School of Public Health, University of Toronto; Sunnybrook Hospital, The University of Toronto; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; Department of Laboratory Medicine and Pathobiology, University of Toronto; Toronto Health Economics and Technology Assessment Collaborative(THETA) and University of Toronto.
Chris Bauch
David N Fisman
R Fowler
Jeffrey C Kwong
Allison McGeer
Marija Zivkovic Gojovic
Murray Krahn
University of Toronto · CA3M (United States) · USInstitute for Clinical Evaluative Sciences · CAToronto Public Health · CAUniversity of Guelph · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This work contributes informed estimates to the current debate about the pandemic (H1N1) 2009 mass immunization program's economic merits. We performed a cost-utility analysis of the (H1N1) 2009 mass immunization program in Ontario, Canada's most populous province. The analysis is based on a simulation model of a pandemic (H1N1) 2009 outbreak, surveillance data, and administrative data. We consider no immunization versus mass immunization reaching 30% of the population. Immunization program costs are expected to be $118 million in Ontario. Our analysis indicates this program will reduce influenza cases by 50%, preventing 35 deaths, and cutting treatment costs in half. A pandemic (H1N1) 2009 immunization program is likely to be highly cost-effective.

Identifiers

PMID20043032
PMCPMC2795773
OpenAlexW2006854980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.